A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2, PHASE3

Enrollment: 342

Sponsor: Priovant Therapeutics, Inc.

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years 2. Scalp biopsy consistent with LPP 3. Active and symptomatic LPP at screening and baseline- 4. Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2 Exclusion Criteria: 1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer). 2. High risk of thrombosis or cardiovascular disease 3. High risk of herpes zoster 4. Active or recent infection

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07532603). StuddyBuddy aggregates publicly available trial information.